ZAI LAB LIMITED Accounts Receivable
ZAI LAB LIMITED (ZLAB) had Accounts Receivable of $69.59 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $69.59M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $54.07M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $106.12M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $85.38M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $69.59M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $54.07M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $106.12M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $85.38M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $88.50M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $76.56M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $85.18M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $49.97M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $69.64M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $60.42M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $59.20M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $41.60M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $47.28M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $43.35M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $39.96M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $27.74M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $27.05M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $33.39M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $47.47M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $21.02M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $18.03M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $8.81M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $5.17M 10-K · filed 2022-03-01 | |
| 2020-06-30 | $7.02M 6-K · filed 2020-09-11 | |
| 2019-12-31 | $3.79M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $3.92M 6-K · filed 2020-01-21 | |
| 2018-12-31 | $90.00K 20-F · filed 2020-04-29 | $89.71K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |